Borshchev Yu Yu, Sonin D L, Burovenko I Yu, Borshchev V Yu, Cheburkin Yu V, Borshcheva O V, Galagudza M M
Almazov National Medical Research Center of the Ministry of Health of the Russian Federation, St. Petersburg, Russia.
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia.
J Evol Biochem Physiol. 2022;58(6):2058-2069. doi: 10.1134/S0022093022060321. Epub 2022 Dec 22.
Numerous experimental and clinical studies have shown the effectiveness of various probiotic strains in metabolic disorders, gastrointestinal and liver diseases, immune system pathology. The effects of probiotics on cardiovascular dysfunction are less well known. The development and validation of a new experimental model in rats, including obesity, acute colon inflammation and antibiotic-induced dysbiosis, with common characteristics of systemic inflammatory response syndrome (SIRS), became the basis for investigating the effects of probiotic drugs on myocardial resistance to ischemic-reperfusion injury (IRI) using an in vivo model of infarction after coronary occlusion. A 24% increase in myocardial infarction compared to intact animals ( < 0.05) and significant changes in leukogram, biochemical and immunological parameters were found in Wistar rats with SIRS modelling. Introduction of a mixture of strains of (LA-5) and subsp. (BB-12) to animals with SIRS reduced infarct size to a value close to the control. Rats treated with LA-5 and BB-12 also showed normalization of the leukocyte count, bile acids, transforming growth factor-β, interleukins: IL-1α, IL-2, IL-6, IL-8, tumor necrosis factor-α, lipopolysaccharide and monocyte chemoattractant protein-1 in blood in comparison with the SIRS group and with the groups treated with other probiotic strains. The obtained data convincingly show the prospects for further study of the cardiotropic potential of probiotic microorganisms in translational studies.
大量实验和临床研究表明，各种益生菌菌株在代谢紊乱、胃肠道和肝脏疾病、免疫系统病理学方面具有有效性。益生菌对心血管功能障碍的影响鲜为人知。一种新的大鼠实验模型的开发和验证，包括肥胖、急性结肠炎症和抗生素诱导的生态失调，具有全身炎症反应综合征（SIRS）的共同特征，成为了使用冠状动脉闭塞后梗死的体内模型研究益生菌药物对心肌抵抗缺血再灌注损伤（IRI）影响的基础。与正常动物相比，SIRS模型的Wistar大鼠心肌梗死增加了24%（<0.05），并且在白细胞计数、生化和免疫参数方面发现了显著变化。将嗜酸乳杆菌（LA-5）和双歧杆菌亚种（BB-12）的菌株混合物引入患有SIRS的动物体内，可将梗死面积减小至接近对照组的值。与SIRS组和用其他益生菌菌株治疗的组相比，用LA-5和BB-12治疗的大鼠血液中的白细胞计数、胆汁酸、转化生长因子-β、白细胞介素：IL-1α、IL-2、IL-6、IL-8、肿瘤坏死因子-α、脂多糖和单核细胞趋化蛋白-1也显示正常化。所获得的数据令人信服地表明，在转化研究中进一步研究益生菌微生物的心脏otropic潜力具有前景。
